As drug development grows increasingly complex, collaboration is no longer optional—it is essential. From combination therapies to shared data strategies, the industry is shifting toward more integrated partnerships aimed at improving patient outcomes.
In a recent interview with Oxford Global, Denise Steckel, Head of Clinical Collaborations Development, Genentech explored how collaboration models are evolving—and why getting them right is critical for future innovation.
From Monotherapy to Combination Thinking
A major shift in modern medicine is the move from monotherapy to combination therapies. Rather than relying on a single drug, researchers are increasingly combining treatments to better address complex diseases and expand patient reach.
This approach not only enhances therapeutic potential but also deepens understanding of disease biology—unlocking new opportunities for innovation.
Strategic vs. Transactional Partnerships
Not all collaborations are created equal. Steckel distinguishes between transactional collaborations, such as early-phase studies, and strategic partnerships that span multiple programmes and long-term goals.
However, even small, early-stage collaborations should be treated with a long-term mindset. Many phase one studies evolve into larger, late-stage programmes, making early relationship-building critical.
Choosing the Right Partner
Successful partnerships are built on mutual selection and shared value. Companies must align not only on scientific goals but also on long-term commitment, as collaborations often span multiple phases of development.
Flexibility is also key. While organisational priorities may shift, strong collaboration frameworks can adapt across therapeutic areas.
Driving Better Patient Outcomes
At their core, collaborations are about improving patient care. By combining therapies with complementary mechanisms of action, companies can create more effective treatment options—many of which are now reaching regulatory approval.
These partnerships enable deeper insights into disease and open new pathways for treatment.
Speed and Execution Matter
With increasing competition, there is growing pressure to accelerate study timelines. Organisations like Roche are focused on expediting trial execution—bringing therapies to patients faster while maintaining quality.
Overcoming Barriers
Collaboration is not without challenges. Differences in processes, systems, and corporate cultures can create friction.
The solution lies in understanding the “why” behind each organisation’s approach and finding common ground. Successful collaborations require compromise, openness, and a willingness to adapt.
Leadership in a Collaborative Era
Effective collaboration depends on leadership. Key qualities include curiosity, flexibility, and commitment—along with a genuine willingness to learn from partners.
“It’s not one way,” Steckel emphasised. “You have to make it work together.”
The Future of Collaboration
Clinical collaborations are becoming faster, more complex, and increasingly data-driven. Discussions around data sharing, regulatory requirements, and long-term study outputs are intensifying.
As timelines accelerate and expectations evolve, collaboration will continue to be a moving target—requiring constant alignment and communication.
Looking Ahead
The future of drug development will be shaped by how well organisations work together. Those that can build strong, strategic partnerships—balancing speed, science, and shared goals—will be best positioned to deliver the next generation of therapies.
In a landscape defined by complexity, collaboration is no longer just a strategy. It is the foundation of progress.